BR0316523A - Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente - Google Patents
Composto, composição farmacêutica e método para tratar ou prevenir câncer em um pacienteInfo
- Publication number
- BR0316523A BR0316523A BR0316523-0A BR0316523A BR0316523A BR 0316523 A BR0316523 A BR 0316523A BR 0316523 A BR0316523 A BR 0316523A BR 0316523 A BR0316523 A BR 0316523A
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- patient
- treating
- compound
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA E MéTODO PARA TRATAR OU PREVENIR CâNCER EM UM PACIENTE". A presente invenção diz respeito no geral aos peptídeos, que inibem a angiogênese, a migração celular, a invasão celular e a proliferação celular, aos métodos de fabricar peptídeos que inibem a angiogênese, a migração celular, a invasão celular e a proliferação celular, às composições farmacêuticas destes peptídeos e métodos de usar estes peptídeos e composições farmacêuticas destes peptídeos para tratar doenças associadas com a vascularização aberrante.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42917402P | 2002-11-25 | 2002-11-25 | |
US47553903P | 2003-06-02 | 2003-06-02 | |
PCT/US2003/038175 WO2004047771A2 (en) | 2002-11-25 | 2003-11-25 | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0316523A true BR0316523A (pt) | 2005-10-18 |
Family
ID=32397181
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0316523-0A BR0316523A (pt) | 2002-11-25 | 2003-11-25 | Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente |
BR0316550-7A BR0316550A (pt) | 2002-11-25 | 2003-11-25 | Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente, e para detectar câncer em um paciente |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0316550-7A BR0316550A (pt) | 2002-11-25 | 2003-11-25 | Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente, e para detectar câncer em um paciente |
Country Status (14)
Country | Link |
---|---|
US (2) | US20050020810A1 (pt) |
EP (2) | EP1594521A4 (pt) |
JP (2) | JP2006514116A (pt) |
KR (2) | KR20050097494A (pt) |
AU (2) | AU2003298726A1 (pt) |
BR (2) | BR0316523A (pt) |
CA (2) | CA2507045A1 (pt) |
EA (2) | EA200500871A1 (pt) |
HR (2) | HRP20050584A2 (pt) |
MX (2) | MXPA05005545A (pt) |
NO (2) | NO20053111L (pt) |
NZ (2) | NZ540363A (pt) |
PL (2) | PL377763A1 (pt) |
WO (2) | WO2004063213A2 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050097494A (ko) * | 2002-11-25 | 2005-10-07 | 아테뉴온, 엘엘씨 | 혈관신생, 세포 이동, 세포 침투 및 증식을 저해하는펩타이드, 그것의 조성물 및 그것의 용도 |
WO2005114194A1 (en) * | 2004-05-21 | 2005-12-01 | Mds Inc. Doing Business Through Its Mds Pharma Services Division | Method of quantifying the cell-binding properties of a medical device |
US20060078535A1 (en) * | 2004-10-13 | 2006-04-13 | The Regents Of The University Of Michigan | Anticancer compounds and methods |
EP1843779A2 (en) * | 2005-02-01 | 2007-10-17 | Attenuon, LLC | Compositions containing the anti-angiogenic phscn-peptide |
JP2008528635A (ja) | 2005-02-01 | 2008-07-31 | アテニュオン,エルエルシー | Ac−PHSCN−NH2の酸付加塩 |
AU2016213759B2 (en) * | 2006-11-08 | 2018-03-29 | Chongxi Yu | Transdermal delivery systems of peptides and related compounds |
JP5424887B2 (ja) * | 2006-11-08 | 2014-02-26 | チョンシー ユー | ペプチド及び関連化合物の経皮送達システム |
CN102459313A (zh) | 2009-05-08 | 2012-05-16 | 上海泰飞尔生化技术有限公司 | 多肽和多肽相关化合物的高穿透力前药组合物 |
KR101228668B1 (ko) | 2010-09-17 | 2013-01-31 | 가톨릭대학교 산학협력단 | 혈관신생 억제 활성을 갖는 펩타이드 및 이의 용도 |
GB2510488B (en) | 2011-06-23 | 2020-04-08 | Univ Texas | Identifying peptides at the single molecule level |
US11435358B2 (en) | 2011-06-23 | 2022-09-06 | Board Of Regents, The University Of Texas System | Single molecule peptide sequencing |
WO2016069124A1 (en) * | 2014-09-15 | 2016-05-06 | Board Of Regents, The University Of Texas System | Improved single molecule peptide sequencing |
CN102417540A (zh) * | 2011-11-21 | 2012-04-18 | 中国药科大学 | 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用 |
JP6206987B2 (ja) * | 2012-05-11 | 2017-10-04 | メディカス バイオサイエンシーズ,エルエルシー | 網膜剥離の処置のための生体適合性ヒドロゲル製剤 |
US20160286801A1 (en) | 2013-03-15 | 2016-10-06 | Suncor Energy Inc. | Herbicidal Compositions |
JP5970439B2 (ja) * | 2013-09-20 | 2016-08-17 | チョンシー ユー | ペプチド及び関連化合物の経皮送達システム |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
EP0051682B1 (en) * | 1980-05-13 | 1984-09-05 | Mitsubishi Kasei Corporation | Cysteine derivatives and process for their preparation |
US4440788A (en) * | 1980-05-13 | 1984-04-03 | Mitsubishi Chemical Industries, Limited | Cysteine derivatives |
US4394519A (en) * | 1982-01-19 | 1983-07-19 | Research Corporation | Amino acid blocking agents |
GB8504253D0 (en) * | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
DE3815221C2 (de) * | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
US5091176A (en) * | 1988-11-02 | 1992-02-25 | W. R. Grace & Co.-Conn. | Polymer-modified peptide drugs having enhanced biological and pharmacological activities |
US5443816A (en) | 1990-08-08 | 1995-08-22 | Rhomed Incorporated | Peptide-metal ion pharmaceutical preparation and method |
US5229366A (en) * | 1990-10-23 | 1993-07-20 | Fuji Photo Film Co., Ltd. | Peptide-containing polyethylene glycol derivatives and application thereof |
US5149801A (en) * | 1990-11-21 | 1992-09-22 | The Regents Of The University Of California | Boronated porphyrin compounds |
US5561220A (en) | 1991-02-08 | 1996-10-01 | Diatech, Inc. | Technetium-99m labeled peptides for imaging inflammation |
US5698155A (en) * | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US5556609A (en) | 1992-02-20 | 1996-09-17 | Rhomed Incorporated | YIGSR peptide radiopharmaceutical applications |
US5608110A (en) * | 1993-06-15 | 1997-03-04 | Bracco International B.V. | Heteroatom-bearing ligands and metal complexes thereof |
US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
ATE186222T1 (de) | 1995-03-14 | 1999-11-15 | Siemens Ag | Ultraschallzerstäuber mit abnehmbarer präzisionsdosiereinheit |
PT814861E (pt) * | 1995-03-14 | 2002-09-30 | Siemens Ag | Pulverizador ultra-sonico com uma unidade de dosagem de precisao amovivel |
US5618513A (en) * | 1995-06-07 | 1997-04-08 | Mallinckrodt Medical, Inc. | Method for preparing radiolabeled peptides |
MY147327A (en) * | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
AU4412297A (en) * | 1996-09-10 | 1998-04-02 | Burnham Institute, The | Tumor homing molecules, conjugates derived therefrom, and methods of using sa me |
US6331409B1 (en) * | 1996-11-21 | 2001-12-18 | The Regents Of The University Of Michigan | Methods and compositions for wound healing |
US6001965A (en) * | 1996-11-21 | 1999-12-14 | The Regents Of The University Of Michigan | Anticancer compounds and methods |
US6025150A (en) * | 1996-11-21 | 2000-02-15 | The Regents Of The University Of Michigan | Methods and compositions for wound healing |
DE69824352T2 (de) * | 1997-01-14 | 2005-06-30 | Kaneka Corp. | Verfahren zur herstellung von cystein derivaten |
US5994309A (en) * | 1997-07-25 | 1999-11-30 | Angstrom Pharmaceuticals, Inc. | Anti-invasive and anti-angiogenic compositions and methods |
EP1015884B1 (en) * | 1997-09-10 | 2008-08-06 | The Burnham Institute | Methods of identifying molecules that home to angiogenic vasculature in tumors |
US5954047A (en) | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
EP1159292A2 (en) * | 1998-08-14 | 2001-12-05 | Administrators of The Tulane Educational Fund | Compounds having growth hormone releasing activity |
EP1388013B1 (en) | 2001-01-18 | 2007-07-11 | The Regents Of The University Of Michigan | Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer |
KR20050097494A (ko) * | 2002-11-25 | 2005-10-07 | 아테뉴온, 엘엘씨 | 혈관신생, 세포 이동, 세포 침투 및 증식을 저해하는펩타이드, 그것의 조성물 및 그것의 용도 |
-
2003
- 2003-11-25 KR KR1020057009447A patent/KR20050097494A/ko not_active Application Discontinuation
- 2003-11-25 US US10/722,843 patent/US20050020810A1/en not_active Abandoned
- 2003-11-25 WO PCT/US2003/037895 patent/WO2004063213A2/en not_active Application Discontinuation
- 2003-11-25 EP EP03812058A patent/EP1594521A4/en not_active Withdrawn
- 2003-11-25 PL PL377763A patent/PL377763A1/pl not_active Application Discontinuation
- 2003-11-25 AU AU2003298726A patent/AU2003298726A1/en not_active Abandoned
- 2003-11-25 KR KR1020057009356A patent/KR20050096917A/ko not_active Application Discontinuation
- 2003-11-25 WO PCT/US2003/038175 patent/WO2004047771A2/en not_active Application Discontinuation
- 2003-11-25 US US10/723,144 patent/US7517855B2/en not_active Expired - Fee Related
- 2003-11-25 JP JP2005510345A patent/JP2006514116A/ja active Pending
- 2003-11-25 BR BR0316523-0A patent/BR0316523A/pt not_active IP Right Cessation
- 2003-11-25 MX MXPA05005545A patent/MXPA05005545A/es unknown
- 2003-11-25 CA CA002507045A patent/CA2507045A1/en not_active Abandoned
- 2003-11-25 NZ NZ540363A patent/NZ540363A/en unknown
- 2003-11-25 NZ NZ540889A patent/NZ540889A/en not_active IP Right Cessation
- 2003-11-25 EA EA200500871A patent/EA200500871A1/ru unknown
- 2003-11-25 MX MXPA05005469A patent/MXPA05005469A/es not_active Application Discontinuation
- 2003-11-25 BR BR0316550-7A patent/BR0316550A/pt not_active IP Right Cessation
- 2003-11-25 CA CA002506813A patent/CA2506813A1/en not_active Abandoned
- 2003-11-25 AU AU2003297609A patent/AU2003297609A1/en not_active Abandoned
- 2003-11-25 EP EP03796483A patent/EP1569678A4/en not_active Withdrawn
- 2003-11-25 EA EA200500870A patent/EA200500870A1/ru unknown
- 2003-11-25 JP JP2005512876A patent/JP2006515866A/ja active Pending
- 2003-11-25 PL PL377701A patent/PL377701A1/pl not_active Application Discontinuation
-
2005
- 2005-06-21 HR HR20050584A patent/HRP20050584A2/hr not_active Application Discontinuation
- 2005-06-21 HR HR20050585A patent/HRP20050585A2/xx not_active Application Discontinuation
- 2005-06-24 NO NO20053111A patent/NO20053111L/no not_active Application Discontinuation
- 2005-06-24 NO NO20053112A patent/NO20053112L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0316523A (pt) | Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente | |
BR0310099A (pt) | método para tratar dislipidemia ou uma doença associada com a dislipidemia | |
BR0010524A (pt) | Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico | |
DE60231439D1 (de) | Mitotische kinesinhemmer | |
DE60234278D1 (de) | Mitotische kinesin-hemmer | |
BRPI0518315B8 (pt) | compostos de tiazol que modulam a atividade da proteína hsp90, métodos de inibição, tratamento e indução associados e composição farmacêutica | |
BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
DE69533112D1 (de) | Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken | |
BR0212078A (pt) | Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto | |
DE60329756D1 (de) | Mitotische kinesin-hemmer | |
DE60329990D1 (de) | Mitotische kinesin-hemmer | |
PA8493701A1 (es) | Compuestos para tratar la obesidad | |
BR0310092A (pt) | Combinação de compostos orgânicos | |
BR0214962A (pt) | Composição para tratar distúrbios neurocerebrovasculares | |
ATE450269T1 (de) | Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten | |
BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
BRPI0417959A (pt) | anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável | |
BR0108175A (pt) | Derivados de piperazina e piperidina para o tratamento ou a prevenção de danos neuronais | |
WO2008079270A3 (en) | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis | |
BR112022005757A2 (pt) | Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma | |
BR0215395A (pt) | Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue | |
BR0201524A (pt) | Tratamento de combinação para ansiedade e depressão | |
BR0315942A (pt) | Tratamento de doenças e condições mediadas pelo aumento de fosforilação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010. |